Research ExplorerPublicationsLeukocyte count restoration under dabrafenib treatment in a ...

Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia

Standard

Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia : case report. / Orouji, Elias; Ziegler, Birgit; Umansky, Viktor; Gebhardt, Christoffer; Utikal, Jochen.

In: MEDICINE, Vol. 93, No. 28, 12.2014, p. e161.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Orouji, E, Ziegler, B, Umansky, V, Gebhardt, C & Utikal, J 2014, 'Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report', MEDICINE, vol. 93, no. 28, pp. e161. https://doi.org/10.1097/MD.0000000000000161

APA

Orouji, E., Ziegler, B., Umansky, V., Gebhardt, C., & Utikal, J. (2014). Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report. MEDICINE, 93(28), e161. https://doi.org/10.1097/MD.0000000000000161

Vancouver

Orouji E, Ziegler B, Umansky V, Gebhardt C, Utikal J. Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report. MEDICINE. 2014 Dec;93(28):e161. https://doi.org/10.1097/MD.0000000000000161

Bibtex

@article{176b3e94cc574622b154d9a41c008ec3,
title = "Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report",
abstract = "Recent advances in melanoma therapy have influenced the management of metastatic patients. Inhibitors of the BRAF/MEK/ERK signaling cascade have been proven highly effective in the metastatic disease although displaying different side effects. Here, we report a patient with BRAF V600E-mutated stage IV melanoma who developed a severe leukopenia upon targeted therapy with the BRAF inhibitor vemurafenib. Interestingly, the immediate therapeutic switch to a different BRAF inhibitor 'dabrafenib? had no negative influence on the leukocyte count. This case supports recent studies, which showed a differential influence of different BRAF inhibitors on patients' leukocytes despite similar clinical efficacy in melanoma.",
keywords = "Antineoplastic Agents, Female, Humans, Imidazoles, Indoles, Leukocyte Count, Leukopenia, Melanoma, Middle Aged, Oximes, Proto-Oncogene Proteins B-raf, Skin Neoplasms, Sulfonamides, Case Reports, Journal Article, Research Support, Non-U.S. Gov't",
author = "Elias Orouji and Birgit Ziegler and Viktor Umansky and Christoffer Gebhardt and Jochen Utikal",
year = "2014",
month = dec,
doi = "10.1097/MD.0000000000000161",
language = "English",
volume = "93",
pages = "e161",
journal = "MEDICINE",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "28",

}

RIS

TY - JOUR

T1 - Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia

T2 - case report

AU - Orouji, Elias

AU - Ziegler, Birgit

AU - Umansky, Viktor

AU - Gebhardt, Christoffer

AU - Utikal, Jochen

PY - 2014/12

Y1 - 2014/12

N2 - Recent advances in melanoma therapy have influenced the management of metastatic patients. Inhibitors of the BRAF/MEK/ERK signaling cascade have been proven highly effective in the metastatic disease although displaying different side effects. Here, we report a patient with BRAF V600E-mutated stage IV melanoma who developed a severe leukopenia upon targeted therapy with the BRAF inhibitor vemurafenib. Interestingly, the immediate therapeutic switch to a different BRAF inhibitor 'dabrafenib? had no negative influence on the leukocyte count. This case supports recent studies, which showed a differential influence of different BRAF inhibitors on patients' leukocytes despite similar clinical efficacy in melanoma.

AB - Recent advances in melanoma therapy have influenced the management of metastatic patients. Inhibitors of the BRAF/MEK/ERK signaling cascade have been proven highly effective in the metastatic disease although displaying different side effects. Here, we report a patient with BRAF V600E-mutated stage IV melanoma who developed a severe leukopenia upon targeted therapy with the BRAF inhibitor vemurafenib. Interestingly, the immediate therapeutic switch to a different BRAF inhibitor 'dabrafenib? had no negative influence on the leukocyte count. This case supports recent studies, which showed a differential influence of different BRAF inhibitors on patients' leukocytes despite similar clinical efficacy in melanoma.

KW - Antineoplastic Agents

KW - Female

KW - Humans

KW - Imidazoles

KW - Indoles

KW - Leukocyte Count

KW - Leukopenia

KW - Melanoma

KW - Middle Aged

KW - Oximes

KW - Proto-Oncogene Proteins B-raf

KW - Skin Neoplasms

KW - Sulfonamides

KW - Case Reports

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1097/MD.0000000000000161

DO - 10.1097/MD.0000000000000161

M3 - SCORING: Journal article

C2 - 25526431

VL - 93

SP - e161

JO - MEDICINE

JF - MEDICINE

SN - 0025-7974

IS - 28

ER -